In this post, I’d like to introduce the Human liver Lysosomes developed by Sekisui-Xenotech, which have opened up a new era in catabolism models. Read on to learn more, and also to download a case study demonstrating the use of lysosomes for catabolism of human IgG.

Following up on my series of posts based on Dr Chris Bohl’s work at Sekisui Xenotech, in this post I invite you to take a look at the work he has published, together with Dr Christopher Seib, Maciej Czerwinski, Zell Woodworth and David Buckley, Ph.D., illustrating the characterization of isolated human liver lysosomes, and validating them as test systems for in vitro assessment of catabolic stability of biologics drugs entering the cell by the endosomal–lysosomal pathway.